基于网络的应用程序预测脓毒症患者重组人血栓调节蛋白治疗潜在目标表型:三项多中心注册研究分析
该研究利用三项多中心脓毒症注册数据,开发并验证机器学习模型预测既往识别的rhTM目标表型,预测因子包括血小板计数、PT-INR、纤维蛋白原、纤维蛋白原/纤维蛋白降解产物比值和D-二聚体。模型开发队列n=3694,验证队列n=1184,各队列约8-9%患者具有目标表型。验证队列C统计量0.996(95%CI 0.993-0.998),敏感度0.991,特异度0.967;预测目标患者(n=142)中rhTM使用与较低住院死亡率相关(校正风险差-31.3% [-53.5 to -9.1%])。作者认为该网络应用可能使研究rhTM治疗异质性的临床医生和研究者受益。
要点
- 模型预测因子为血小板计数、PT-INR、纤维蛋白原、纤维蛋白原/纤维蛋白降解产物比值和D-二聚体,已实现为网络应用。
- 验证队列中预测rhTM目标表型的C统计量为0.996(95%CI 0.993-0.998),敏感度0.991,特异度0.967。
- 各队列约8-9%的脓毒症患者具有rhTM目标表型。
- 验证队列预测目标患者(n=142)中,rhTM使用与住院死亡率降低相关(校正风险差-31.3% [-53.5 to -9.1%])。
- 近期随机对照试验未能证明rhTM对脓毒症有益,但研究人群异质性导致争议持续。
适用人群与场景
- 脓毒症患者,来自三项多中心注册研究;模型开发队列n=3694,验证队列n=1184。
- 各队列中约8-9%的患者具有rhTM目标表型。
诊断标准与关键阈值
- rhTM目标表型为既往研究识别的特定表型,本研究模型用于预测该表型存在。
- 预测因子:血小板计数、PT-INR、纤维蛋白原、纤维蛋白原/纤维蛋白降解产物比值、D-二聚体。
研究设计与关键结果
- 研究类型:基于三项多中心注册研究的机器学习模型开发与验证。
- 模型开发使用两项注册(n=3694),验证使用剩余一项注册(n=1184)。
- 验证队列中模型预测rhTM目标表型的C统计量为0.996(95%CI 0.993-0.998),敏感度0.991,特异度0.967。
- 验证队列预测目标患者(n=142)中,rhTM使用与较低住院死亡率相关(校正风险差-31.3% [-53.5 to -9.1%])。
证据类型、等级与局限
- 证据类型:基于多中心注册数据的机器学习模型开发与验证研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为该网络应用可能使研究rhTM治疗效应异质性及其机制的临床医生和研究者受益。
- 在预测目标患者(n=142)中,rhTM使用与住院死亡率降低相关(校正风险差-31.3% [-53.5 to -9.1%])。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
A recent randomised controlled trial failed to demonstrate a beneficial effect of recombinant human thrombomodulin (rhTM) on sepsis. However, there is still controversy in the effects of rhTM for sepsis due to the heterogeneity of the study population. We previously identified patients with a distinct phenotype that could be a potential target of rhTM therapy (rhTM target phenotype). However, for application in the clinical setting, a simple tool for determining this target is necessary. Thus, using three multicentre sepsis registries, we aimed to develop and validate a machine learning model for predicting presence of the target phenotype that we previously identified for targeted rhTM therapy. The predictors were platelet count, PT-INR, fibrinogen, fibrinogen/fibrin degradation products, and D-dimer. We also implemented the model as a web-based application. Two of the three registries were used for model development (n = 3694), and the remaining registry was used for validation (n = 1184). Approximately 8-9% of patients had the rhTM target phenotype in each cohort. In the validation, the C statistic of the developed model for predicting the rhTM target phenotype was 0.996 (95% CI 0.993-0.998), with a sensitivity of 0.991 and a specificity of 0.967. Among patients who were predicted to have the potential target phenotype (predicted target patients) in the validation cohort (n = 142), rhTM use was associated with a lower in-hospital mortality (adjusted risk difference, - 31.3% [- 53.5 to - 9.1%]). The developed model was able to accurately predict the rhTM target phenotype. The model, which is available as a web-based application, could profoundly benefit clinicians and researchers investigating the heterogeneity in the treatment effects of rhTM and its mechanisms.
参考来源
- Goto T, Kudo D, Uchimido R, et al. Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicentre registries. Crit Care. 2022. PMID: 35590381. doi:10.1186/s13054-022-04020-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。